Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
14.86
+0.05 (0.34%)
Feb 4, 2026, 3:04 PM CST
SHE:002365 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 791.78 | 833.34 | 959.37 | 1,426 | 1,546 | 1,166 |
Other Revenue | 5.47 | 5.47 | 13.52 | 36.57 | 19.54 | 6.87 |
| 797.25 | 838.81 | 972.89 | 1,462 | 1,565 | 1,173 | |
Revenue Growth (YoY) | 1.07% | -13.78% | -33.48% | -6.58% | 33.47% | -14.42% |
Cost of Revenue | 679.67 | 672.79 | 722.37 | 991.13 | 1,212 | 820.06 |
Gross Profit | 117.57 | 166.02 | 250.52 | 471.32 | 353.73 | 352.8 |
Selling, General & Admin | 75.78 | 80.61 | 176.42 | 249.77 | 154.58 | 166.85 |
Research & Development | 32.68 | 36.97 | 41.5 | 40.45 | 53.04 | 46.66 |
Other Operating Expenses | 14.81 | 9.16 | 10.09 | 13.66 | 11.58 | 10.09 |
Operating Expenses | 122 | 126.05 | 226.39 | 301.41 | 228.94 | 225.14 |
Operating Income | -4.42 | 39.97 | 24.12 | 169.91 | 124.79 | 127.66 |
Interest Expense | -0.92 | -0.59 | -0.37 | -0.66 | -2.44 | -1.2 |
Interest & Investment Income | 36.98 | 40.78 | 27.39 | 12.62 | 24.2 | 25.99 |
Currency Exchange Gain (Loss) | 9.17 | 9.17 | 5.64 | 21.55 | -4.09 | -8.54 |
Other Non Operating Income (Expenses) | -5.18 | -1.02 | -0.43 | -0.64 | -0.7 | -0.51 |
EBT Excluding Unusual Items | 35.62 | 88.32 | 56.35 | 202.77 | 141.76 | 143.39 |
Impairment of Goodwill | -0.52 | -0.52 | -8.25 | - | - | - |
Gain (Loss) on Sale of Investments | 4.02 | 4.43 | -34.55 | -30.34 | -0.28 | -1.19 |
Gain (Loss) on Sale of Assets | 0.97 | 0.19 | 45.02 | -0.38 | 0.25 | -0.01 |
Asset Writedown | -16.02 | -15.36 | -42.06 | -3.65 | -3.02 | -15.45 |
Legal Settlements | -10.02 | -10.02 | -23.3 | -22.73 | -13.61 | -4.94 |
Other Unusual Items | 6.2 | 3.82 | 12.84 | 7.4 | 4.75 | 8.78 |
Pretax Income | 20.26 | 70.86 | 6.05 | 153.06 | 129.85 | 130.58 |
Income Tax Expense | 3.01 | 11.15 | 34.47 | 20.34 | 10.81 | 11.92 |
Earnings From Continuing Operations | 17.25 | 59.71 | -28.41 | 132.72 | 119.05 | 118.66 |
Minority Interest in Earnings | 8.16 | 2.06 | 16.1 | 7.63 | -7.63 | -13.1 |
Net Income | 25.41 | 61.77 | -12.31 | 140.35 | 111.42 | 105.56 |
Preferred Dividends & Other Adjustments | - | - | - | 0.19 | 3.63 | - |
Net Income to Common | 25.41 | 61.77 | -12.31 | 140.16 | 107.78 | 105.56 |
Net Income Growth | 715.62% | - | - | 25.97% | 5.55% | 17.38% |
Shares Outstanding (Basic) | 290 | 293 | 295 | 294 | 287 | 288 |
Shares Outstanding (Diluted) | 291 | 295 | 295 | 294 | 287 | 289 |
Shares Change (YoY) | -0.95% | - | 0.13% | 2.66% | -0.63% | 0.06% |
EPS (Basic) | 0.09 | 0.21 | -0.04 | 0.48 | 0.38 | 0.37 |
EPS (Diluted) | 0.09 | 0.21 | -0.04 | 0.48 | 0.38 | 0.37 |
EPS Growth | 724.77% | - | - | 26.66% | 2.75% | 17.69% |
Free Cash Flow | 38.75 | -12.33 | 100.46 | 238.21 | 38.76 | 102.25 |
Free Cash Flow Per Share | 0.13 | -0.04 | 0.34 | 0.81 | 0.14 | 0.35 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | - | 0.100 |
Dividend Growth | - | - | - | - | - | -33.33% |
Gross Margin | 14.75% | 19.79% | 25.75% | 32.23% | 22.60% | 30.08% |
Operating Margin | -0.56% | 4.76% | 2.48% | 11.62% | 7.97% | 10.88% |
Profit Margin | 3.19% | 7.36% | -1.27% | 9.58% | 6.88% | 9.00% |
Free Cash Flow Margin | 4.86% | -1.47% | 10.32% | 16.29% | 2.48% | 8.72% |
EBITDA | 91.37 | 152.65 | 159.3 | 293.53 | 240.75 | 240.72 |
EBITDA Margin | 11.46% | 18.20% | 16.37% | 20.07% | 15.38% | 20.52% |
D&A For EBITDA | 95.79 | 112.68 | 135.18 | 123.62 | 115.96 | 113.07 |
EBIT | -4.42 | 39.97 | 24.12 | 169.91 | 124.79 | 127.66 |
EBIT Margin | -0.56% | 4.76% | 2.48% | 11.62% | 7.97% | 10.88% |
Effective Tax Rate | 14.84% | 15.74% | 569.54% | 13.29% | 8.32% | 9.13% |
Revenue as Reported | 797.25 | 838.81 | 972.89 | 1,462 | 1,565 | 1,173 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.